Cargando…

Systematic Review and Meta-Analysis of Observational Studies on the Effectiveness and Safety of Ustekinumab among Patients with Inflammatory Bowel Disease in Eastern and Western Countries

Background: Ustekinumab (UST) is an IL12/23 inhibitor utilized for altering inflammatory responses in inflammatory bowel disease (IBD). Clinical trials and case reports suggested that the effectiveness and safety of UST may differ among IBD patients in Eastern and Western countries. However, related...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, He, Wang, Fang, Wan, Jian, Su, Song, Shi, Yanting, Li, Xiaofei, Wu, Tong, Liang, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004158/ https://www.ncbi.nlm.nih.gov/pubmed/36902681 http://dx.doi.org/10.3390/jcm12051894

Ejemplares similares

Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease
por: Gara, Sirisha K, et al.
Publicado: (2023)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
por: Sandborn, William J, et al.
Publicado: (2020)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
por: Wang, Fang, et al.
Publicado: (2023)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

Corrigendum to: Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
Publicado: (2021)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease
por: Roblin, Xavier, et al.
Publicado: (2023)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Efficacy and safety of ustekinumab in adolescents
por: Kellen, Roselyn, et al.
Publicado: (2016)

Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease
por: Kono, Masashi, et al.
Publicado: (2019)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Effects of Golimumab and Ustekinumab on Circulating Dendritic Cell Migratory Capacity in Inflammatory Bowel Disease
por: Soleto, Irene, et al.
Publicado: (2023)

Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases
por: Viola, Anna, et al.
Publicado: (2021)

The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries
por: Aniwan, Satimai, et al.
Publicado: (2022)

Hypersensitivity Reaction to Ustekinumab in Pediatric and Young Adult Inflammatory Bowel Disease Patients: A Case Series
por: Sunny, Julee, et al.
Publicado: (2022)

Comprehensive Review of Ustekinumab Utilization in Inflammatory Bowel Diseases: Insights from the ClinicalTrials.gov Registry
por: Alorfi, Nasser M, et al.
Publicado: (2023)

The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
por: Chiu, Hsien-Yi, et al.
Publicado: (2015)

Comparison and recommendation of dietary patterns based on nutrients for Eastern and Western patients with inflammatory bowel disease
por: Hou, Yue, et al.
Publicado: (2023)

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
por: Thunberg, Joel, et al.
Publicado: (2022)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
por: Rubín de Célix, Cristina, et al.
Publicado: (2022)

Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study
por: Mitrova, Katarina, et al.
Publicado: (2021)

How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data
por: Gutiérrez, Ana, et al.
Publicado: (2021)

Treatment of Inflammatory Bowel Disease and Pediatric Onset Multiple Sclerosis With Ocrelizumab and Ustekinumab in a JC-virus Positive Adolescent
por: Lambert-Jenkins, Kristin, et al.
Publicado: (2022)

Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study
por: Teresa, Valdés Delgado, et al.
Publicado: (2023)

Letter to the Editor in Response to: Hypersensitivity Reaction to Ustekinumab in Pediatric and Young Adult Inflammatory Bowel Disease Patients: A Case Series
por: Samalik, Joann, et al.
Publicado: (2023)

A Comparison of Aortoiliac Disease between Eastern and Western Countries
por: Joh, Jin Hyun, et al.
Publicado: (2019)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries
por: Kobayashi, Taku, et al.
Publicado: (2018)

Incidence Trends of Inflammatory Bowel Disease in a Southern European Country: A Mirror of the Western World?
por: Santiago, Mafalda, et al.
Publicado: (2022)

The change of healthcare service in Chinese patients with inflammatory bowel disease during the pandemic: a national multicenter cross-sectional study
por: Li, Xiaofei, et al.
Publicado: (2023)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Resilience Interventions Conducted in Western and Eastern Countries—A Systematic Review
por: Blessin, Manpreet, et al.
Publicado: (2022)

A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment
por: Yu, Qianying, et al.
Publicado: (2022)

Inflammatory Bowel Disease in Children of Middle Eastern Descent
por: Naidoo, Christina Mai Ying, et al.
Publicado: (2014)

Fatigue in patients with inflammatory bowel disease in Eastern China
por: Gong, Shan-Shan, et al.
Publicado: (2021)

Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
por: Jeffrey, Angus W., et al.
Publicado: (2023)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_05t357ugt019ijgsqdktj84oo7